

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
18 June 2020 (18.06.2020)



(10) International Publication Number
WO 2020/120983 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 7/08 (2006.01)
A61K 38/00 (2006.01) C12N 9/64 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/GB2019/053539

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

13 December 2019 (13.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1820295.2 13 December 2018 (13.12.2018) GB

(71) Applicant: **BICYCLERD LIMITED** [GB/GB]; Building
900, Babraham Research Campus, Cambridge CB22 3AT
(GB).

(72) Inventors: **STACE, Catherine**; BicycleTX Limited,
Building 900, Babraham Research Campus, Cambridge
CB22 3AT (GB). **TEUFEL, Daniel**; BicycleTX Limited,
Building 900, Babraham Research Campus, Cambridge
CB22 3AT (GB). **WALKER, Edward**; BicycleTX Limited,
Building 900, Babraham Research Campus, Cambridge
CB22 3AT (GB).

(74) Agent: **GIBSON, Mark** et al.; Sagittarius IP, Marlow In-
ternational, Parkway, Marlow, Buckinghamshire SL7 1YL
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP

(57) Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP), such as the collagen binding site of MT1-MMP. The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.



WO 2020/120983 A1

BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP**FIELD OF THE INVENTION**

The present invention relates to polypeptides which are covalently bound to aromatic
5 molecular scaffolds such that two or more peptide loops are subtended between attachment
points to the scaffold. In particular, the invention describes peptides which are high affinity
binders of membrane type 1 metalloprotease (MT1-MMP), such as the collagen binding site
of MT1-MMP. The invention also describes drug conjugates comprising said peptides,
10 conjugated to one or more effector and/or functional groups which have utility in imaging and
targeted cancer therapy.

BACKGROUND OF THE INVENTION

Cyclic peptides are able to bind with high affinity and target specificity to protein targets and
hence are an attractive molecule class for the development of therapeutics. In fact, several
15 cyclic peptides are already successfully used in the clinic, as for example the antibacterial
peptide vancomycin, the immunosuppressant drug cyclosporine or the anti-cancer drug
octreotide (Driggers *et al.* (2008), Nat Rev Drug Discov 7 (7), 608-24). Good binding properties
result from a relatively large interaction surface formed between the peptide and the target as
well as the reduced conformational flexibility of the cyclic structures. Typically, macrocycles
20 bind to surfaces of several hundred square angstrom, as for example the cyclic peptide
CXCR4 antagonist CVX15 (400 Å²; Wu *et al.* (2007), Science 330, 1066-71), a cyclic peptide
with the Arg-Gly-Asp motif binding to integrin αVβ3 (355 Å²) (Xiong *et al.* (2002), Science 296
(5565), 151-5) or the cyclic peptide inhibitor upain-1 binding to urokinase-type plasminogen
activator (603 Å²; Zhao *et al.* (2007), J Struct Biol 160 (1), 1-10).

25 Due to their cyclic configuration, peptide macrocycles are less flexible than linear peptides,
leading to a smaller loss of entropy upon binding to targets and resulting in a higher binding
affinity. The reduced flexibility also leads to locking target-specific conformations, increasing
binding specificity compared to linear peptides. This effect has been exemplified by a potent
and selective inhibitor of matrix metalloproteinase 8 (MMP-8) which lost its selectivity over
30 other MMPs when its ring was opened (Cherney *et al.* (1998), J Med Chem 41 (11), 1749-51).
The favorable binding properties achieved through macrocyclization are even more
pronounced in multicyclic peptides having more than one peptide ring as for example in
vancomycin, nisin and actinomycin.

35 Different research teams have previously tethered polypeptides with cysteine residues to a
synthetic molecular structure (Kemp and McNamara (1985), J. Org. Chem; Timmerman *et*

5 *al.* (2005), ChemBioChem). Meloen and co-workers had used tris(bromomethyl)benzene and related molecules for rapid and quantitative cyclisation of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces (Timmerman *et al.* (2005), ChemBioChem). Methods for the generation of candidate drug compounds wherein said compounds are generated by linking cysteine containing polypeptides to a molecular scaffold as for example tris(bromomethyl)benzene are disclosed in WO 2004/077062 and WO 2006/078161.

10 Phage display-based combinatorial approaches have been developed to generate and screen large libraries of bicyclic peptides to targets of interest (Heinis *et al.* (2009), Nat Chem Biol 5 (7), 502-7 and WO 2009/098450). Briefly, combinatorial libraries of linear peptides containing three cysteine residues and two regions of six random amino acids (Cys-(Xaa)₆-Cys-(Xaa)₆-Cys) were displayed on phage and cyclised by covalently linking the cysteine side chains to a small molecule (tris-(bromomethyl)benzene).

15 SUMMARY OF THE INVENTION

According to a first aspect of the invention, there is provided a peptide ligand specific for the collagen binding site of MT1-MMP comprising a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and an aromatic molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold.

25 According to a further aspect of the invention, there is provided a drug conjugate comprising a peptide ligand as defined herein conjugated to one or more effector and/or functional groups.

According to a further aspect of the invention, there is provided a pharmaceutical composition comprising a peptide ligand or a drug conjugate as defined herein in combination with one or more pharmaceutically acceptable excipients.

30 According to a further aspect of the invention, there is provided a peptide ligand or drug conjugate as defined herein for use in preventing, suppressing or treating a disease or disorder mediated by MT1-MMP.

DETAILED DESCRIPTION OF THE INVENTION

35 In one embodiment, said loop sequences comprise 6 amino acids.

In a further embodiment, said loop sequences comprise three cysteine residues separated by two loop sequences both of which consists of 6 amino acids.

In one embodiment, the peptide ligand comprises an amino acid sequence selected from:

5 $C_i-X_1-X_2-X_3-X_4-X_5-X_6-C_{ii}-L-F-G-X_{10}-Y-X_{12}-C_{iii}$ (SEQ ID NO: 1)

wherein X_1-X_6 , X_{10} and X_{12} represent any natural or non-natural amino acid and C_i , C_{ii} and C_{iii} represent first, second and third cysteine residues, respectively or a pharmaceutically acceptable salt thereof.

10 In one embodiment, X_1 represents S, P, HyP or D.

In one embodiment, X_2 represents F, L, Y, V, H or I.

In one embodiment, X_3 represents D, S or E.

15

In one embodiment, X_4 represents W, T, R or I.

In one embodiment, X_5 represents W, E, D, S, R, A or H.

20 In one embodiment, X_6 represents I, T, M, V, L or Q.

In one embodiment, X_{10} represents D, E, N, S, T or Q.

In one embodiment, X_{12} represents T, R, S, N, K, D or H.

25

In one embodiment, the peptide ligand of $C_i-X_1-X_2-X_3-X_4-X_5-X_6-C_{ii}-L-F-G-X_{10}-Y-X_{12}-C_{iii}$ (SEQ ID NO: 1) is selected from:

CPYSWETCLFGDYRC (SEQ ID NO: 2);

C[HyP]YSWETCLFGDYRC (SEQ ID NO: 3);

30 CSLDWETCLFGDYRC (SEQ ID NO: 4);

CDVEWETCLFGDYRC (SEQ ID NO: 5);

CPYSWDTCLFGDYRC (SEQ ID NO: 6);

CPHDWETCLFGDYRC (SEQ ID NO: 7);

CPYSWDMCLFGDYRC (SEQ ID NO: 8);

35 CPYSWDVCLFGDYRC (SEQ ID NO: 9);

CPYSWDLCLFGDYRC (SEQ ID NO: 10);

CPYSWSQCLFGDYRC (SEQ ID NO: 11);

CPYSWSTCLFGDYRC (SEQ ID NO: 12);
 CPYSWDICLFGDYRC (SEQ ID NO: 13);
 CPYSWRTCLFGDYRC (SEQ ID NO: 14);
 CPYSWETCLFGDYSC (SEQ ID NO: 15);
 5 CPYSWETCLFGEYNC (SEQ ID NO: 16);
 CPYSWETCLFGEYKC (SEQ ID NO: 17);
 CPYSWETCLFGNYTC (SEQ ID NO: 18);
 CPYSWETCLFGDYDC (SEQ ID NO: 19);
 CPYSWETCLFGSYRC (SEQ ID NO: 20);
 10 CPYSWETCLFGSYTC (SEQ ID NO: 21);
 CPYSWETCLFGTYTC (SEQ ID NO: 22);
 CPYDWATCLFGDYRC (SEQ ID NO: 23);
 CPYDTWTCLFGDYRC (SEQ ID NO: 24);
 CPYDRHTCLFGDYRC (SEQ ID NO: 25);
 15 CPYDIRTCLFGDYRC (SEQ ID NO: 26); and
 CPLSWSTCLFGQYHC (SEQ ID NO: 27).

In a further embodiment, the peptide ligand of C_i-X₁-X₂-X₃-X₄-X₅-X₆-C_{ii}-L-F-G-X₁₀-Y-X₁₂-C_{iii} (SEQ ID NO: 1) is selected from:

20 A-(SEQ ID NO: 2)-A (BCY1025);
 Ac-(SEQ ID NO: 2) (BCY1027);
 [DOTA]-G-[Sar]₅-(SEQ ID NO: 2) (BCY1388);
 A-(SEQ ID NO: 3)-A (BCY1029);
 A-(SEQ ID NO: 4)-A (BCY1030);
 25 A-(SEQ ID NO: 5)-A (BCY1031);
 A-(SEQ ID NO: 6)-A (BCY1032);
 A-(SEQ ID NO: 7)-A (BCY1034);
 A-(SEQ ID NO: 8)-A (BCY1035);
 A-(SEQ ID NO: 9)-A (BCY1036);
 30 A-(SEQ ID NO: 10)-A (BCY1037);
 A-(SEQ ID NO: 11)-A (BCY1038);
 A-(SEQ ID NO: 12)-A (BCY1039);
 A-(SEQ ID NO: 13)-A (BCY1040);
 A-(SEQ ID NO: 14)-A (BCY1041);
 35 A-(SEQ ID NO: 15)-A (BCY1042);
 A-(SEQ ID NO: 16)-A (BCY1043);
 A-(SEQ ID NO: 17)-A (BCY1044);

A-(SEQ ID NO: 18)-A (BCY1045);
A-(SEQ ID NO: 19)-A (BCY1046);
A-(SEQ ID NO: 20)-A (BCY1047);
A-(SEQ ID NO: 21)-A (BCY1048);
5 A-(SEQ ID NO: 22)-A (BCY1049);
A-(SEQ ID NO: 23)-A (BCY1051);
A-(SEQ ID NO: 24)-A (BCY1052);
A-(SEQ ID NO: 25)-A (BCY1053);
A-(SEQ ID NO: 26)-A (BCY1054); and
10 A-(SEQ ID NO: 27)-A (BCY1056).

In a further embodiment, the molecular scaffold is TBMB and the peptide ligand of C_i-X₁-X₂-X₃-X₄-X₅-X₆-C_{ii}-L-F-G-X₁₀-Y-X₁₂-C_{iii} (SEQ ID NO: 1) is selected from:

A-(SEQ ID NO: 2)-A (BCY1025);
15 Ac-(SEQ ID NO: 2) (BCY1027);
[DOTA]-G-[Sar]₅-(SEQ ID NO: 2) (BCY1388);
A-(SEQ ID NO: 3)-A (BCY1029);
A-(SEQ ID NO: 4)-A (BCY1030);
A-(SEQ ID NO: 5)-A (BCY1031);
20 A-(SEQ ID NO: 6)-A (BCY1032);
A-(SEQ ID NO: 7)-A (BCY1034);
A-(SEQ ID NO: 8)-A (BCY1035);
A-(SEQ ID NO: 9)-A (BCY1036);
A-(SEQ ID NO: 10)-A (BCY1037);
25 A-(SEQ ID NO: 11)-A (BCY1038);
A-(SEQ ID NO: 12)-A (BCY1039);
A-(SEQ ID NO: 13)-A (BCY1040);
A-(SEQ ID NO: 14)-A (BCY1041);
A-(SEQ ID NO: 15)-A (BCY1042);
30 A-(SEQ ID NO: 16)-A (BCY1043);
A-(SEQ ID NO: 17)-A (BCY1044);
A-(SEQ ID NO: 18)-A (BCY1045);
A-(SEQ ID NO: 19)-A (BCY1046);
A-(SEQ ID NO: 20)-A (BCY1047);
35 A-(SEQ ID NO: 21)-A (BCY1048);
A-(SEQ ID NO: 22)-A (BCY1049);
A-(SEQ ID NO: 23)-A (BCY1051);

A-(SEQ ID NO: 24)-A (BCY1052);
A-(SEQ ID NO: 25)-A (BCY1053);
A-(SEQ ID NO: 26)-A (BCY1054); and
A-(SEQ ID NO: 27)-A (BCY1056).

5

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art, such as in the arts of peptide chemistry, cell culture and phage display, nucleic acid chemistry and biochemistry. Standard techniques are used for molecular biology, genetic and biochemical methods (see
10 Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 3rd ed., 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel *et al.*, Short Protocols in Molecular Biology (1999) 4th ed., John Wiley & Sons, Inc.), which are incorporated herein by reference.

Nomenclature

15 Numbering

When referring to amino acid residue positions within the peptides of the invention, cysteine residues (C_i, C_{ii} and C_{iii}) are omitted from the numbering as they are invariant, therefore, the numbering of amino acid residues within the peptides of the invention is referred to as below:

20 C_i-P₁-Y₂-S₃-W₄-E₅-T₆-C_{ii}-L₇-F₈-G₉-D₁₀-Y₁₁-R₁₂-C_{iii} (SEQ ID NO: 2).

For the purpose of this description, all bicyclic peptides are assumed to be cyclised with either TBMB (1,3,5-tris(bromomethyl)benzene) yielding a tri-substituted 1,3,5-trimethylbenzene structure. Cyclisation with TBMB occurs on C_i, C_{ii}, and C_{iii}.

25

Molecular Format

N- or C-terminal extensions to the bicycle core sequence are added to the left or right side of the sequence, separated by a hyphen. For example, an N-terminal βAla-Sar10-Ala tail would be denoted as:

30 βAla-Sar10-A-(SEQ ID NO: X).

Inversed Peptide Sequences

In light of the disclosure in Nair *et al* (2003) J Immunol 170(3), 1362-1373, it is envisaged that the peptide sequences disclosed herein would also find utility in their retro-inverso form.

35 For example, the sequence is reversed (i.e. N-terminus becomes C-terminus and *vice versa*) and their stereochemistry is likewise also reversed (i.e. D-amino acids become L-amino acids and *vice versa*).

Peptide Ligands

A peptide ligand, as referred to herein, refers to a peptide covalently bound to a molecular scaffold. Typically, such peptides comprise two or more reactive groups (i.e. cysteine residues) which are capable of forming covalent bonds to the scaffold, and a sequence subtended between said reactive groups which is referred to as the loop sequence, since it forms a loop when the peptide is bound to the scaffold. In the present case, the peptides comprise at least three cysteine residues (referred to herein as C_i, C_{ii} and C_{iii}), and form at least two loops on the scaffold.

Advantages of the Peptide Ligands

Certain bicyclic peptides of the present invention have a number of advantageous properties which enable them to be considered as suitable drug-like molecules for injection, inhalation, nasal, ocular, oral or topical administration. Such advantageous properties include:

- Species cross-reactivity. Certain ligands demonstrate cross-reactivity across PBPs from different bacterial species and hence are able to treat infections caused by multiple species of bacteria. Other ligands may be highly specific for the PBPs of certain bacterial species which may be advantageous for treating an infection without collateral damage to the beneficial flora of the patient;

- Protease stability. Bicyclic peptide ligands should ideally demonstrate stability to plasma proteases, epithelial ("membrane-anchored") proteases, gastric and intestinal proteases, lung surface proteases, intracellular proteases and the like. Protease stability should be maintained between different species such that a bicycle lead candidate can be developed in animal models as well as administered with confidence to humans;

- Desirable solubility profile. This is a function of the proportion of charged and hydrophilic versus hydrophobic residues and intra/inter-molecular H-bonding, which is important for formulation and absorption purposes;

- An optimal plasma half-life in the circulation. Depending upon the clinical indication and treatment regimen, it may be required to develop a bicyclic peptide for short exposure in an acute illness management setting, or develop a bicyclic peptide with enhanced retention in the circulation, and is therefore optimal for the management of more chronic disease states. Other factors driving the desirable plasma half-life are requirements of sustained exposure for maximal therapeutic efficiency versus the accompanying toxicology due to sustained

exposure of the agent; and

- Selectivity. Certain peptide ligands of the invention demonstrate selectivity for MT1-MMP, but does not cross-react with MMP isoforms, such as MMP-1, MMP-2, MMP-15 and MMP-16.

Pharmaceutically Acceptable Salts

It will be appreciated that salt forms are within the scope of this invention, and references to peptide ligands include the salt forms of said ligands.

10

The salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods such as methods described in *Pharmaceutical Salts: Properties, Selection, and Use*, P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: 3-90639-026-8, Hardcover, 388 pages, August 2002. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.

15

Acid addition salts (mono- or di-salts) may be formed with a wide variety of acids, both inorganic and organic. Examples of acid addition salts include mono- or di-salts formed with an acid selected from the group consisting of acetic, 2,2-dichloroacetic, adipic, alginic, ascorbic (e.g. L-ascorbic), L-aspartic, benzenesulfonic, benzoic, 4-acetamidobenzoic, butanoic, (+) camphoric, camphor-sulfonic, (+)-(1S)-camphor-10-sulfonic, capric, caproic, caprylic, cinnamic, citric, cyclamic, dodecylsulfuric, ethane-1,2-disulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, formic, fumaric, galactaric, gentisic, glucoheptonic, D-gluconic, glucuronic (e.g. D-glucuronic), glutamic (e.g. L-glutamic), α -oxoglutaric, glycolic, hippuric, hydrohalic acids (e.g. hydrobromic, hydrochloric, hydriodic), isethionic, lactic (e.g. (+)-L-lactic, (\pm)-DL-lactic), lactobionic, maleic, malic, (-)-L-malic, malonic, (\pm)-DL-mandelic, methanesulfonic, naphthalene-2-sulfonic, naphthalene-1,5-disulfonic, 1-hydroxy-2-naphthoic, nicotinic, nitric, oleic, orotic, oxalic, palmitic, pamoic, phosphoric, propionic, pyruvic, L-pyroglutamic, salicylic, 4-amino-salicylic, sebacic, stearic, succinic, sulfuric, tannic, (+)-L-tartaric, thiocyanic, *p*-toluenesulfonic, undecylenic and valeric acids, as well as acylated amino acids and cation exchange resins.

25

30

One particular group of salts consists of salts formed from acetic, hydrochloric, hydriodic, phosphoric, nitric, sulfuric, citric, lactic, succinic, maleic, malic, isethionic, fumaric, benzenesulfonic, toluenesulfonic, sulfuric, methanesulfonic (mesylate), ethanesulfonic,

35

naphthalenesulfonic, valeric, propanoic, butanoic, malonic, glucuronic and lactobionic acids. One particular salt is the hydrochloride salt. Another particular salt is the acetate salt.

5 If the compound is anionic, or has a functional group which may be anionic (e.g., -COOH may be -COO^-), then a salt may be formed with an organic or inorganic base, generating a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Li^+ , Na^+ and K^+ , alkaline earth metal cations such as Ca^{2+} and Mg^{2+} , and other cations such as Al^{3+} or Zn^+ . Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e., NH_4^+) and substituted ammonium ions (e.g., NH_3R^+ , NH_2R_2^+ , NHR_3^+ ,
10 NR_4^+). Examples of some suitable substituted ammonium ions are those derived from: methylamine, ethylamine, diethylamine, propylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine. An example of a common quaternary ammonium ion is $\text{N}(\text{CH}_3)_4^+$.

15 Where the peptides of the invention contain an amine function, these may form quaternary ammonium salts, for example by reaction with an alkylating agent according to methods well known to the skilled person. Such quaternary ammonium compounds are within the scope of the peptides of the invention.

20

Modified Derivatives

It will be appreciated that modified derivatives of the peptide ligands as defined herein are within the scope of the present invention. Examples of such suitable modified derivatives include one or more modifications selected from: N-terminal and/or C-terminal modifications;
25 replacement of one or more amino acid residues with one or more non-natural amino acid residues (such as replacement of one or more polar amino acid residues with one or more isosteric or isoelectronic amino acids; replacement of one or more non-polar amino acid residues with other non-natural isosteric or isoelectronic amino acids); addition of a spacer group; replacement of one or more oxidation sensitive amino acid residues with one or more
30 oxidation resistant amino acid residues; replacement of one or more amino acid residues with an alanine, replacement of one or more L-amino acid residues with one or more D-amino acid residues; N-alkylation of one or more amide bonds within the bicyclic peptide ligand; replacement of one or more peptide bonds with a surrogate bond; peptide backbone length modification; substitution of the hydrogen on the alpha-carbon of one or more amino acid
35 residues with another chemical group, modification of amino acids such as cysteine, lysine, glutamate/aspartate and tyrosine with suitable amine, thiol, carboxylic acid and phenol-reactive reagents so as to functionalise said amino acids, and introduction or replacement of

amino acids that introduce orthogonal reactivities that are suitable for functionalisation, for example azide or alkyne-group bearing amino acids that allow functionalisation with alkyne or azide-bearing moieties, respectively.

5 In one embodiment, the modified derivative comprises an N-terminal and/or C-terminal modification. In a further embodiment, wherein the modified derivative comprises an N-terminal modification using suitable amino-reactive chemistry, and/or C-terminal modification using suitable carboxy-reactive chemistry. In a further embodiment, said N-terminal or C-terminal modification comprises addition of an effector group, including but not limited to a
10 cytotoxic agent, a radiochelator or a chromophore.

In a further embodiment, the modified derivative comprises an N-terminal modification. In a further embodiment, the N-terminal modification comprises an N-terminal acetyl group. In this embodiment, the N-terminal cysteine group (the group referred to herein as C_i) is capped with
15 acetic anhydride or other appropriate reagents during peptide synthesis leading to a molecule which is N-terminally acetylated. This embodiment provides the advantage of removing a potential recognition point for aminopeptidases and avoids the potential for degradation of the bicyclic peptide.

20 In an alternative embodiment, the N-terminal modification comprises the addition of a molecular spacer group which facilitates the conjugation of effector groups and retention of potency of the bicyclic peptide to its target.

In a further embodiment, the modified derivative comprises a C-terminal modification. In a further embodiment, the C-terminal modification comprises an amide group. In this
25 embodiment, the C-terminal cysteine group (the group referred to herein as C_{iii}) is synthesized as an amide during peptide synthesis leading to a molecule which is C-terminally amidated. This embodiment provides the advantage of removing a potential recognition point for carboxypeptidase and reduces the potential for proteolytic degradation of the bicyclic peptide.

30

In one embodiment, the modified derivative comprises replacement of one or more amino acid residues with one or more non-natural amino acid residues. In this embodiment, non-natural amino acids may be selected having isosteric/isoelectronic side chains which are neither recognised by degradative proteases nor have any adverse effect upon target potency.

35

Alternatively, non-natural amino acids may be used having constrained amino acid side chains, such that proteolytic hydrolysis of the nearby peptide bond is conformationally and

sterically impeded. In particular, these concern proline analogues, bulky sidechains, C α -disubstituted derivatives (for example, aminoisobutyric acid, Aib), and cyclo amino acids, a simple derivative being amino-cyclopropylcarboxylic acid.

5 In one embodiment, the modified derivative comprises the addition of a spacer group. In a further embodiment, the modified derivative comprises the addition of a spacer group to the N-terminal cysteine (C_i) and/or the C-terminal cysteine (C_{iii}).

10 In one embodiment, the modified derivative comprises replacement of one or more oxidation sensitive amino acid residues with one or more oxidation resistant amino acid residues.

In one embodiment, the modified derivative comprises replacement of one or more charged amino acid residues with one or more hydrophobic amino acid residues. In an alternative embodiment, the modified derivative comprises replacement of one or more hydrophobic amino acid residues with one or more charged amino acid residues. The correct balance of charged versus hydrophobic amino acid residues is an important characteristic of the bicyclic peptide ligands. For example, hydrophobic amino acid residues influence the degree of plasma protein binding and thus the concentration of the free available fraction in plasma, while charged amino acid residues (in particular arginine) may influence the interaction of the peptide with the phospholipid membranes on cell surfaces. The two in combination may influence half-life, volume of distribution and exposure of the peptide drug, and can be tailored according to the clinical endpoint. In addition, the correct combination and number of charged versus hydrophobic amino acid residues may reduce irritation at the injection site (if the peptide drug has been administered subcutaneously).

25 In one embodiment, the modified derivative comprises replacement of one or more L-amino acid residues with one or more D-amino acid residues. This embodiment is believed to increase proteolytic stability by steric hindrance and by a propensity of D-amino acids to stabilise β -turn conformations (Tugyi *et al* (2005) PNAS, 102(2), 413–418).

30 In one embodiment, the modified derivative comprises removal of any amino acid residues and substitution with alanines. This embodiment provides the advantage of removing potential proteolytic attack site(s).

35 It should be noted that each of the above mentioned modifications serve to deliberately improve the potency or stability of the peptide. Further potency improvements based on modifications may be achieved through the following mechanisms:

- Incorporating hydrophobic moieties that exploit the hydrophobic effect and lead to lower off rates, such that higher affinities are achieved;
 - 5 - Incorporating charged groups that exploit long-range ionic interactions, leading to faster on rates and to higher affinities (see for example Schreiber *et al*, *Rapid, electrostatically assisted association of proteins* (1996), *Nature Struct. Biol.* 3, 427-31); and
 - Incorporating additional constraint into the peptide, by for example constraining side
10 chains of amino acids correctly such that loss in entropy is minimal upon target binding, constraining the torsional angles of the backbone such that loss in entropy is minimal upon target binding and introducing additional cyclisations in the molecule for identical reasons.
- (for reviews see Gentilucci *et al*, *Curr. Pharmaceutical Design*, (2010), 16, 3185-203, and
15 Nestor *et al*, *Curr. Medicinal Chem* (2009), 16, 4399-418).

Isotopic variations

The present invention includes all pharmaceutically acceptable (radio)isotope-labeled peptide ligands of the invention, wherein one or more atoms are replaced by atoms having the same
20 atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature, and peptide ligands of the invention, wherein metal chelating groups are attached (termed "effector") that are capable of holding relevant (radio)isotopes, and peptide ligands of the invention, wherein certain functional groups are covalently replaced with relevant (radio)isotopes or isotopically labelled functional groups.

25 Examples of isotopes suitable for inclusion in the peptide ligands of the invention comprise isotopes of hydrogen, such as ^2H (D) and ^3H (T), carbon, such as ^{11}C , ^{13}C and ^{14}C , chlorine, such as ^{36}Cl , fluorine, such as ^{18}F , iodine, such as ^{123}I , ^{125}I and ^{131}I , nitrogen, such as ^{13}N and ^{15}N , oxygen, such as ^{15}O , ^{17}O and ^{18}O , phosphorus, such as ^{32}P , sulfur, such as ^{35}S , copper,
30 such as ^{64}Cu , gallium, such as ^{67}Ga or ^{68}Ga , yttrium, such as ^{90}Y and lutetium, such as ^{177}Lu , and Bismuth, such as ^{213}Bi .

Certain isotopically-labelled peptide ligands of the invention, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The
35 peptide ligands of the invention can further have valuable diagnostic properties in that they can be used for detecting or identifying the formation of a complex between a labelled compound and other molecules, peptides, proteins, enzymes or receptors. The detecting or

identifying methods can use compounds that are labelled with labelling agents such as radioisotopes, enzymes, fluorescent substances, luminous substances (for example, luminol, luminol derivatives, luciferin, aequorin and luciferase), etc. The radioactive isotopes tritium, *i.e.* ^3H (T), and carbon-14, *i.e.* ^{14}C , are particularly useful for this purpose in view of their ease
5 of incorporation and ready means of detection.

Substitution with heavier isotopes such as deuterium, *i.e.* ^2H (D), may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements, and hence may be preferred in some
10 circumstances.

Substitution with positron emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O and ^{13}N , can be useful in Positron Emission Topography (PET) studies for examining target occupancy.

15 Isotopically-labeled compounds of peptide ligands of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.

20 **Aromatic Molecular scaffold**

References herein to the term "aromatic molecular scaffold" refer to any molecular scaffold as defined herein which contains an aromatic carbocyclic or heterocyclic ring system.

It will be appreciated that the aromatic molecular scaffold may comprise an aromatic moiety.
25 Examples of suitable aromatic moieties within the aromatic scaffold include biphenylene, terphenylene, naphthalene or anthracene.

It will also be appreciated that the aromatic molecular scaffold may comprise a heteroaromatic moiety. Examples of suitable heteroaromatic moieties within the aromatic
30 scaffold include pyridine, pyrimidine, pyrrole, furan and thiophene.

It will also be appreciated that the aromatic molecular scaffold may comprise a halomethylarene moiety, such as a bis(bromomethyl)benzene, a tris(bromomethyl)benzene, a tetra(bromomethyl)benzene or derivatives thereof.

35 Non-limiting examples of aromatic molecular scaffolds include: bis-, tris-, or tetra(halomethyl)benzene; bis-, tris-, or tetra(halomethyl)pyridine; bis-, tris-, or tetra(halomethyl)pyridazine; bis-, tris-, or tetra(halomethyl)pyrimidine; bis-, tris-, or

5 tetra(halomethyl)pyrazine; bis-, tris-, or tetra(halomethyl)-1,2,3-triazine; bis-, tris-, or tetra(halomethyl)-1,2,4-triazine; bis-, tris-, or tetra(halomethyl)pyrrole, -furan, -thiophene; bis-, tris-, or tetra(halomethyl)imidazole, -oxazole, -thiazol; bis-, tris-, or tetra(halomethyl)-3H-pyrazole, -isooxazole, -isothiazol; bis-, tris-, or tetra(halomethyl)biphenylene; bis-, tris-, or tetra(halomethyl)terphenylene; 1,8-bis(halomethyl)naphthalene; bis-, tris-, or tetra(halomethyl)anthracene; and bis-, tris-, or tetra(2-halomethylphenyl)methane.

More specific examples of aromatic molecular scaffolds include: 1,2-bis(halomethyl)benzene; 3,4-bis(halomethyl)pyridine; 3,4-bis(halomethyl)pyridazine; 4,5-bis(halomethyl)pyrimidine; 4,5-bis(halomethyl)pyrazine; 4,5-bis(halomethyl)-1,2,3-triazine; 10 5,6-bis(halomethyl)-1,2,4-triazine; 3,4-bis(halomethyl)pyrrole, -furan, -thiophene and other regioisomers; 4,5-bis(halomethyl)imidazole, -oxazole, -thiazol; 4,5-bis(halomethyl)-3H-pyrazole, -isooxazole, -isothiazol; 2,2'-bis(halomethyl)biphenylene; 2,2'-bis(halomethyl)terphenylene; 1,8-bis(halomethyl)naphthalene; 1,10-bis(halomethyl)anthracene; bis(2-halomethylphenyl)methane; 1,2,3-tris(halomethyl)benzene; 15 2,3,4-tris(halomethyl)pyridine; 2,3,4-tris(halomethyl)pyridazine; 3,4,5-tris(halomethyl)pyrimidine; 4,5,6-tris(halomethyl)-1,2,3-triazine; 2,3,4-tris(halomethyl)pyrrole, -furan, -thiophene; 2,4,5-bis(halomethyl)imidazole, -oxazole, -thiazol; 3,4,5-bis(halomethyl)-1H-pyrazole, -isooxazole, -isothiazol; 2,4,2'-tris(halomethyl)biphenylene; 2,3',2''-tris(halomethyl)terphenylene; 1,3,8-tris(halomethyl)naphthalene; 1,3,10-tris(halomethyl)anthracene; bis(2-halomethylphenyl)methane; 1,2,4,5-tetra(halomethyl)benzene; 1,2,4,5-tetra(halomethyl)pyridine; 2,4,5,6-tetra(halomethyl)pyrimidine; 2,3,4,5-tetra(halomethyl)pyrrole, -furan, -thiophene; 2,2',6,6'-tetra(halomethyl)biphenylene; 2,2'',6,6''-tetra(halomethyl) terphenylene; 2,3,5,6-tetra(halomethyl)naphthalene and 2,3,7,8-tetra(halomethyl)anthracene; and bis(2,4-bis(halomethyl)phenyl)methane.

As noted in the foregoing documents, the molecular scaffold may be a small molecule, such as a small organic molecule.

30

In one embodiment the molecular scaffold may be a macromolecule. In one embodiment the molecular scaffold is a macromolecule composed of amino acids, nucleotides or carbohydrates.

35 In one embodiment the molecular scaffold comprises reactive groups that are capable of reacting with functional group(s) of the polypeptide to form covalent bonds.

The molecular scaffold may comprise chemical groups which form the linkage with a peptide, such as amines, thiols, alcohols, ketones, aldehydes, nitriles, carboxylic acids, esters, alkenes, alkynes, azides, anhydrides, succinimides, maleimides, alkyl halides and acyl halides.

5

In one embodiment, the molecular scaffold may comprise or may consist of tris(bromomethyl)benzene, especially 1,3,5-tris(bromomethyl)benzene ('TBMB'), or a derivative thereof.

10 In one embodiment, the molecular scaffold is 2,4,6-tris(bromomethyl)mesitylene. This molecule is similar to 1,3,5-tris(bromomethyl)benzene but contains three additional methyl groups attached to the benzene ring. This has the advantage that the additional methyl groups may form further contacts with the polypeptide and hence add additional structural constraint.

15

The molecular scaffold of the invention contains chemical groups that allow functional groups of the polypeptide of the encoded library of the invention to form covalent links with the molecular scaffold. Said chemical groups are selected from a wide range of functionalities including amines, thiols, alcohols, ketones, aldehydes, nitriles, carboxylic acids, esters, alkenes, alkynes, anhydrides, succinimides, maleimides, azides, alkyl halides and acyl halides.

20

Scaffold reactive groups that could be used on the molecular scaffold to react with thiol groups of cysteines are alkyl halides (or also named halogenoalkanes or haloalkanes).

25

Examples include bromomethylbenzene (the scaffold reactive group exemplified by TBMB) or iodoacetamide. Other scaffold reactive groups that are used to selectively couple compounds to cysteines in proteins are maleimides, $\alpha\beta$ unsaturated carbonyl containing compounds and α -halomethylcarbonyl containing compounds. Examples of maleimides which may be used as molecular scaffolds in the invention include: tris-(2-maleimidoethyl)amine, tris-(2-maleimidoethyl)benzene, tris-(maleimido)benzene. An example of an α -halomethylcarbonyl containing compound is N,N',N''-(benzene-1,3,5-triyl)tris(2-bromoacetamide). Selenocysteine is also a natural amino acid which has a similar reactivity to cysteine and can be used for the same reactions. Thus, wherever cysteine is mentioned, it is typically acceptable to substitute selenocysteine unless the context suggests otherwise.

30

35

Effector and Functional Groups

According to a further aspect of the invention, there is provided a drug conjugate comprising a peptide ligand as defined herein conjugated to one or more effector and/or functional groups.

5

Effector and/or functional groups can be attached, for example, to the N and/or C termini of the polypeptide, to an amino acid within the polypeptide, or to the molecular scaffold.

Appropriate effector groups include antibodies and parts or fragments thereof. For instance, an effector group can include an antibody light chain constant region (CL), an antibody CH1 heavy chain domain, an antibody CH2 heavy chain domain, an antibody CH3 heavy chain domain, or any combination thereof, in addition to the one or more constant region domains. An effector group may also comprise a hinge region of an antibody (such a region normally being found between the CH1 and CH2 domains of an IgG molecule).

15

In a further embodiment of this aspect of the invention, an effector group according to the present invention is an Fc region of an IgG molecule. Advantageously, a peptide ligand-effector group according to the present invention comprises or consists of a peptide ligand Fc fusion having a $t_{1/2}$ half-life of a day or more, two days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more or 7 days or more. Most advantageously, the peptide ligand according to the present invention comprises or consists of a peptide ligand Fc fusion having a $t_{1/2}$ half-life of a day or more.

20

Functional groups include, in general, binding groups, drugs, reactive groups for the attachment of other entities, functional groups which aid uptake of the macrocyclic peptides into cells, and the like.

25

The ability of peptides to penetrate into cells will allow peptides against intracellular targets to be effective. Targets that can be accessed by peptides with the ability to penetrate into cells include transcription factors, intracellular signalling molecules such as tyrosine kinases and molecules involved in the apoptotic pathway. Functional groups which enable the penetration of cells include peptides or chemical groups which have been added either to the peptide or the molecular scaffold. Peptides such as those derived from such as VP22, HIV-Tat, a homeobox protein of *Drosophila* (Antennapedia), e.g. as described in Chen and Harrison, Biochemical Society Transactions (2007) Volume 35, part 4, p821; Gupta *et al.* in Advanced Drug Discovery Reviews (2004) Volume 57 9637. Examples of short peptides which have

30

35

been shown to be efficient at translocation through plasma membranes include the 16 amino acid penetratin peptide from *Drosophila Antennapedia* protein (Derossi *et al* (1994) *J Biol. Chem.* Volume 269 p10444), the 18 amino acid 'model amphipathic peptide' (Oehlke *et al* (1998) *Biochim Biophys Acts* Volume 1414 p127) and arginine rich regions of the HIV TAT protein. Non peptidic approaches include the use of small molecule mimics or SMOCs that can be easily attached to biomolecules (Okuyama *et al* (2007) *Nature Methods* Volume 4 p153). Other chemical strategies to add guanidinium groups to molecules also enhance cell penetration (Elson-Scwab *et al* (2007) *J Biol Chem* Volume 282 p13585). Small molecular weight molecules such as steroids may be added to the molecular scaffold to enhance uptake into cells.

One class of functional groups which may be attached to peptide ligands includes antibodies and binding fragments thereof, such as Fab, Fv or single domain fragments. In particular, antibodies which bind to proteins capable of increasing the half-life of the peptide ligand *in vivo* may be used.

In one embodiment, a peptide ligand-effector group according to the invention has a t_{β} half-life selected from the group consisting of: 12 hours or more, 24 hours or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, 7 days or more, 8 days or more, 9 days or more, 10 days or more, 11 days or more, 12 days or more, 13 days or more, 14 days or more, 15 days or more or 20 days or more. Advantageously a peptide ligand-effector group or composition according to the invention will have a t_{β} half-life in the range 12 to 60 hours. In a further embodiment, it will have a t_{β} half-life of a day or more. In a further embodiment still, it will be in the range 12 to 26 hours.

In one particular embodiment of the invention, the functional group is selected from a metal chelator, which is suitable for complexing metal radioisotopes of medicinal relevance.


Possible effector groups also include enzymes, for instance such as carboxypeptidase G2 for use in enzyme/prodrug therapy, where the peptide ligand replaces antibodies in ADEPT.

In one particular embodiment of the invention, the functional group is selected from a drug, such as a cytotoxic agent for cancer therapy. Suitable examples include: alkylating agents such as cisplatin and carboplatin, as well as oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide; Anti-metabolites including purine analogs azathioprine and mercaptopurine or pyrimidine analogs; plant alkaloids and terpenoids including vinca alkaloids

such as Vincristine, Vinblastine, Vinorelbine and Vindesine; Podophyllotoxin and its derivatives etoposide and teniposide; Taxanes, including paclitaxel, originally known as Taxol; topoisomerase inhibitors including camptothecins: irinotecan and topotecan, and type II inhibitors including amsacrine, etoposide, etoposide phosphate, and teniposide. Further agents can include antitumour antibiotics which include the immunosuppressant dactinomycin (which is used in kidney transplantations), doxorubicin, epirubicin, bleomycin, calicheamycins, and others.


In one further particular embodiment of the invention, the cytotoxic agent is selected from maytansinoids (such as DM1) or monomethyl auristatins (such as MMAE).

DM1 is a cytotoxic agent which is a thiol-containing derivative of maytansine and has the following structure:



15

Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent and has the following structure:



In one yet further particular embodiment of the invention, the cytotoxic agent is selected from monomethyl auristatin E (MMAE). Data is presented herein in Figure 1 and Tables 3 and 4 which demonstrates the effects of peptide ligands conjugated to a toxin containing MMAE.

5

In one embodiment, the cytotoxic agent is linked to the bicyclic peptide by a cleavable bond, such as a disulphide bond or a protease sensitive bond. In a further embodiment, the groups adjacent to the disulphide bond are modified to control the hindrance of the disulphide bond, and by this the rate of cleavage and concomitant release of cytotoxic agent.

10

Published work established the potential for modifying the susceptibility of the disulphide bond to reduction by introducing steric hindrance on either side of the disulphide bond (Kellogg *et al* (2011) *Bioconjugate Chemistry*, 22, 717). A greater degree of steric hindrance reduces the rate of reduction by intracellular glutathione and also extracellular (systemic) reducing agents, consequentially reducing the ease by which toxin is released, both inside and outside the cell. Thus, selection of the optimum in disulphide stability in the circulation (which minimises undesirable side effects of the toxin) versus efficient release in the intracellular milieu (which

15

maximises the therapeutic effect) can be achieved by careful selection of the degree of hindrance on either side of the disulphide bond.

5 The hindrance on either side of the disulphide bond is modulated through introducing one or more methyl groups on either the targeting entity (here, the bicyclic peptide) or toxin side of the molecular construct.

10 In one embodiment, the cytotoxic agent and linker is selected from any combinations of those described in WO 2016/067035 (the cytotoxic agents and linkers thereof are herein incorporated by reference).

Synthesis

15 The peptides of the present invention may be manufactured synthetically by standard techniques followed by reaction with a molecular scaffold *in vitro*. When this is performed, standard chemistry may be used. This enables the rapid large scale preparation of soluble material for further downstream experiments or validation. Such methods could be accomplished using conventional chemistry such as that disclosed in Timmerman *et al* (*supra*).

20 Thus, the invention also relates to manufacture of polypeptides selected as set out herein, wherein the manufacture comprises optional further steps as explained below. In one embodiment, these steps are carried out on the end product polypeptide made by chemical synthesis.

25 Peptides can also be extended, to incorporate for example another loop and therefore introduce multiple specificities.

To extend the peptide, it may simply be extended chemically at its N-terminus or C-terminus or within the loops using orthogonally protected lysines (and analogues) using standard solid
30 phase or solution phase chemistry. Standard (bio)conjugation techniques may be used to introduce an activated or activatable N- or C-terminus. Alternatively additions may be made by fragment condensation or native chemical ligation e.g. as described in (Dawson *et al.* 1994. Synthesis of Proteins by Native Chemical Ligation. *Science* 266:776-779), or by enzymes, for example using subtiligase as described in (Chang *et al.* *Proc Natl Acad Sci U S A.* 1994 Dec
35 20; 91(26):12544-8 or in Hikari *et al* *Bioorganic & Medicinal Chemistry Letters* Volume 18, Issue 22, 15 November 2008, Pages 6000-6003).

Alternatively, the peptides may be extended or modified by further conjugation through disulphide bonds. This has the additional advantage of allowing the first and second peptide to dissociate from each other once within the reducing environment of the cell. In this case, the molecular scaffold (e.g. TBMB) could be added during the chemical synthesis of the first peptide so as to react with the three cysteine groups; a further cysteine or thiol could then be appended to the N or C-terminus of the first peptide, so that this cysteine or thiol only reacted with a free cysteine or thiol of the second peptide, forming a disulfide –linked bicyclic peptide-peptide conjugate.

Similar techniques apply equally to the synthesis/coupling of two bicyclic and bispecific macrocycles, potentially creating a tetraspecific molecule.

Furthermore, addition of other functional groups or effector groups may be accomplished in the same manner, using appropriate chemistry, coupling at the N- or C-termini or via side chains. In one embodiment, the coupling is conducted in such a manner that it does not block the activity of either entity.

Pharmaceutical Compositions

According to a further aspect of the invention, there is provided a pharmaceutical composition comprising a peptide ligand as defined herein in combination with one or more pharmaceutically acceptable excipients.

Generally, the present peptide ligands will be utilised in purified form together with pharmacologically appropriate excipients or carriers. Typically, these excipients or carriers include aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and/or buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride and lactated Ringer's. Suitable physiologically-acceptable adjuvants, if necessary to keep a polypeptide complex in suspension, may be chosen from thickeners such as carboxymethylcellulose, polyvinylpyrrolidone, gelatin and alginates.

Intravenous vehicles include fluid and nutrient replenishers and electrolyte replenishers, such as those based on Ringer's dextrose. Preservatives and other additives, such as antimicrobials, antioxidants, chelating agents and inert gases, may also be present (Mack (1982) Remington's Pharmaceutical Sciences, 16th Edition).

The compounds of the invention can be used alone or in combination with another agent or agents. The other agent for use in combination may be for example another antibiotic, or an antibiotic 'adjuvant' such as an agent for improving permeability into Gram-negative bacteria, an inhibitor of resistance determinants or an inhibitor of virulence mechanisms.

5

Suitable antibiotics for use in combination with the compounds of the invention include but are not limited to:

Beta lactams, such as penicillins, cephalosporins, carbapenems or monobactams. Suitable penicillins include oxacillin, methicillin, ampicillin, cloxacillin, carbenicillin, piperacillin, 10 tricarillin, flucloxacillin, and nafcillin; suitable cephalosporins include cefazolin, cefalexin, cefalothin, ceftazidime, cefepime, ceftobiprole, ceftaroline, ceftolozane and cefiderocol; suitable carbapenems include meropenem, doripenem, imipenem, ertapenem, biapenem and tebipenem; suitable monobactams include aztreonam;

Lincosamides such as clindamycin and lincomycin;

15 Macrolides such as azithromycin, clarithromycin, erythromycin, telithromycin and solithromycin;

Tetracyclines such as tigecycline, omadacycline, eravacycline, doxycycline, and minocycline;

Quinolones such as ciprofloxacin, levofloxacin, moxifloxacin, and delafloxacin;

20 Rifamycins such as rifampicin, rifabutin, rifalazil, rifapentine, and rifaximin;

Aminoglycosides such as gentamycin, streptomycin, tobramycin, amikacin and plazomicin;

Glycopeptides such as vancomycin, teichoplanin, telavancin, dalbavancin, and oritavancin,

Pleuromutilins such as lefamulin

Oxazolidinones such as linezolid or tedizolid

25 Polymyxins such as polymyxin B or colistin;

Trimethoprim, iclaprim, sulfamethoxazole;

Metronidazole;

Fidaxomicin;

Mupirocin;

30 Fusidic acid;

Daptomycin;

Murepavidin;

Fosfomicin; and

Nitrofurantoin.

35

Suitable antibiotic 'adjuvants' include but are not limited to:

agents known to improve uptake into bacteria such as outer membrane permeabilisers or efflux pump inhibitors; outer membrane permeabilisers may include polymyxin B nonapeptide or other polymyxin analogues, or sodium edetate;

- 5 inhibitors of resistance mechanisms such as beta-lactamase inhibitors; suitable beta-lactamase inhibitors include clavulanic acid, tazobactam, sulbactam, avibactam, relebactam and nacubactam; and inhibitors of virulence mechanisms such as toxins and secretion systems, including antibodies.

- 10 The compounds of the invention can also be used in combination with biological therapies such as nucleic acid based therapies, antibodies, bacteriophage or phage lysins.

The route of administration of pharmaceutical compositions according to the invention may be any of those commonly known to those of ordinary skill in the art. For therapy, the peptide
15 ligands of the invention can be administered to any patient in accordance with standard techniques. Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eyedrops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol,
20 e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot or reservoir, for example,
25 subcutaneously or intramuscularly. Preferably, the pharmaceutical compositions according to the invention will be administered parenterally. The dosage and frequency of administration will depend on the age, sex and condition of the patient, concurrent administration of other drugs, counterindications and other parameters to be taken into account by the clinician.

- 30 The peptide ligands of this invention can be lyophilised for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective and art-known lyophilisation and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilisation and reconstitution can lead to varying degrees of activity loss and that levels may have to be adjusted upward to compensate.

35

The compositions containing the present peptide ligands or a cocktail thereof can be administered for therapeutic treatments. In certain therapeutic applications, an adequate

amount to accomplish at least partial inhibition, suppression, modulation, killing, or some other measurable parameter, of a population of selected cells is defined as a "therapeutically-effective dose". Amounts needed to achieve this dosage will depend upon the severity of the disease and the general state of the patient's own immune system, but generally range from
5 10 µg to 250 mg of selected peptide ligand per kilogram of body weight, with doses of between 100 µg to 25 mg/kg/dose being more commonly used.

A composition containing a peptide ligand according to the present invention may be utilised in therapeutic settings to treat a microbial infection or to provide prophylaxis to a subject at
10 risk of infection eg undergoing surgery, chemotherapy, artificial ventilation or other condition or planned intervention. In addition, the peptide ligands described herein may be used extracorporeally or *in vitro* selectively to kill, deplete or otherwise effectively remove a target cell population from a heterogeneous collection of cells. Blood from a mammal may be combined extracorporeally with the selected peptide ligands whereby the undesired cells are
15 killed or otherwise removed from the blood for return to the mammal in accordance with standard techniques.

Therapeutic Uses

The bicyclic peptides of the invention have specific utility as high affinity binders of
20 membrane type 1 metalloprotease (MT1-MMP, also known as MMP14). More specifically to the collagen binding region of the hemopexin domain (Arkadash *et al* J. Biol. Chem. 2017, 292(8), 3481-3495). MT1-MMP is a transmembrane metalloprotease that plays a major role in the extracellular matrix remodeling, directly by degrading several of its components and indirectly by activating pro-MMP2. MT1-MMP is crucial for tumor angiogenesis (Sounni *et al*
25 (2002) FASEB J. 16(6), 555-564) and is over-expressed on a variety of solid tumours, therefore the drug conjugates comprising MT1-MMP-binding bicycle peptides of the present invention have particular utility in the targeted treatment of cancer, in particular solid tumours such as non-small cell lung carcinomas. In one embodiment, the bicyclic peptide of the invention is specific for human MT1-MMP. In a further embodiment, the bicyclic peptide of
30 the invention is specific for mouse MT1-MMP. In a yet further embodiment, the bicyclic peptide of the invention is specific for human and mouse MT1-MMP. In a yet further embodiment, the bicyclic peptide of the invention is specific for human, mouse and dog MT1-MMP.

35 Polypeptide ligands of the invention may be employed in *in vivo* therapeutic and prophylactic applications, *in vitro* and *in vivo* diagnostic applications, *in vitro* assay and reagent applications, and the like. Ligands having selected levels of specificity are useful in

applications which involve testing in non-human animals, where cross-reactivity is desirable, or in diagnostic applications, where cross-reactivity with homologues or paralogues needs to be carefully controlled. In some applications, such as vaccine applications, the ability to elicit an immune response to predetermined ranges of antigens can be exploited to tailor a vaccine to specific diseases and pathogens.

Substantially pure peptide ligands of at least 90 to 95% homogeneity are preferred for administration to a mammal, and 98 to 99% or more homogeneity is most preferred for pharmaceutical uses, especially when the mammal is a human. Once purified, partially or to homogeneity as desired, the selected polypeptides may be used diagnostically or therapeutically (including extracorporeally) or in developing and performing assay procedures, immunofluorescent stainings and the like (Lefkovite and Pernis, (1979 and 1981) Immunological Methods, Volumes I and II, Academic Press, NY).

The conjugates of the peptide ligands of the present invention will typically find use in preventing, suppressing or treating cancer, in particular solid tumours such as non-small cell lung carcinomas.

Thus, according to a further aspect of the invention, there are provided drug conjugates of the peptide ligand as defined herein for use in preventing, suppressing or treating cancer, in particular solid tumours such as non-small cell lung carcinomas.

According to a further aspect of the invention, there is provided a method of preventing, suppressing or treating cancer, in particular solid tumours such as non-small cell lung carcinomas which comprises administering to a patient in need thereof a drug conjugate of the peptide ligand as defined herein.

Examples of cancers (and their benign counterparts) which may be treated (or inhibited) include, but are not limited to tumours of epithelial origin (adenomas and carcinomas of various types including adenocarcinomas, squamous carcinomas, transitional cell carcinomas and other carcinomas) such as carcinomas of the bladder and urinary tract, breast, gastrointestinal tract (including the esophagus, stomach (gastric), small intestine, colon, rectum and anus), liver (hepatocellular carcinoma), gall bladder and biliary system, exocrine pancreas, kidney, lung (for example adenocarcinomas, small cell lung carcinomas, non-small cell lung carcinomas, bronchioalveolar carcinomas and mesotheliomas), head and neck (for example cancers of the tongue, buccal cavity, larynx, pharynx, nasopharynx, tonsil, salivary glands, nasal cavity and paranasal sinuses), ovary, fallopian tubes, peritoneum,

vagina, vulva, penis, cervix, myometrium, endometrium, thyroid (for example thyroid follicular carcinoma), adrenal, prostate, skin and adnexae (for example melanoma, basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, dysplastic naevus); haematological malignancies (i.e. leukemias, lymphomas) and premalignant haematological disorders and disorders of borderline malignancy including haematological malignancies and related conditions of lymphoid lineage (for example acute lymphocytic leukemia [ALL], chronic lymphocytic leukemia [CLL], B-cell lymphomas such as diffuse large B-cell lymphoma [DLBCL], follicular lymphoma, Burkitt's lymphoma, mantle cell lymphoma, T-cell lymphomas and leukaemias, natural killer [NK] cell lymphomas, Hodgkin's lymphomas, hairy cell leukaemia, monoclonal gammopathy of uncertain significance, plasmacytoma, multiple myeloma, and post-transplant lymphoproliferative disorders), and haematological malignancies and related conditions of myeloid lineage (for example acute myelogenousleukemia [AML], chronic myelogenousleukemia [CML], chronic myelomonocyticleukemia [CMML], hypereosinophilic syndrome, myeloproliferative disorders such as polycythaemia vera, essential thrombocythaemia and primary myelofibrosis, myeloproliferative syndrome, myelodysplastic syndrome, and promyelocyticleukemia); tumours of mesenchymal origin, for example sarcomas of soft tissue, bone or cartilage such as osteosarcomas, fibrosarcomas, chondrosarcomas, rhabdomyosarcomas, leiomyosarcomas, liposarcomas, angiosarcomas, Kaposi's sarcoma, Ewing's sarcoma, synovial sarcomas, epithelioid sarcomas, gastrointestinal stromal tumours, benign and malignant histiocytomas, and dermatofibrosarcomaprotuberans; tumours of the central or peripheral nervous system (for example astrocytomas, gliomas and glioblastomas, meningiomas, ependymomas, pineal tumours and schwannomas); endocrine tumours (for example pituitary tumours, adrenal tumours, islet cell tumours, parathyroid tumours, carcinoid tumours and medullary carcinoma of the thyroid); ocular and adnexal tumours (for example retinoblastoma); germ cell and trophoblastic tumours (for example teratomas, seminomas, dysgerminomas, hydatidiform moles and choriocarcinomas); and paediatric and embryonal tumours (for example medulloblastoma, neuroblastoma, Wilms tumour, and primitive neuroectodermal tumours); or syndromes, congenital or otherwise, which leave the patient susceptible to malignancy (for example Xeroderma Pigmentosum).

References herein to the term "prevention" involves administration of the protective composition prior to the induction of the disease. "Suppression" refers to administration of the composition after an inductive event, but prior to the clinical appearance of the disease. "Treatment" involves administration of the protective composition after disease symptoms become manifest.

Animal model systems which can be used to screen the effectiveness of the drug conjugates in protecting against or treating the disease are available. The use of animal model systems is facilitated by the present invention, which allows the development of polypeptide ligands which can cross react with human and animal targets, to allow the use of animal models.

5

The invention is further described below with reference to the following examples.

Examples

10 **Materials and Methods**

Peptide Synthesis

Peptide synthesis was based on Fmoc chemistry, using a Symphony peptide synthesiser manufactured by Peptide Instruments and a Syro II synthesiser by MultiSynTech. Standard
15 Fmoc-amino acids were employed (Sigma, Merck), with appropriate side chain protecting groups: where applicable standard coupling conditions were used in each case, followed by deprotection using standard methodology.

Alternatively, peptides were purified using HPLC and following isolation they were modified
20 with 1,3,5-tris(bromomethyl)benzene (TBMB, Sigma). For this, linear peptide was diluted with H₂O up to ~35 mL, ~500 µL of 100 mM TBMB in acetonitrile was added, and the reaction was initiated with ~5 mL of 1 M NH₄HCO₃ in H₂O. The reaction was allowed to proceed for ~30 - 60 min at RT, and lyophilised once the reaction had completed (judged by MALDI). Once completed, 1ml of 1M L-cysteine hydrochloride monohydrate (Sigma) in H₂O was added to
25 the reaction for ~60 min at RT to quench any excess TBMB.

Following lyophilisation, the modified peptide was purified as above, while replacing the Luna C8 with a Gemini C18 column (Phenomenex), and changing the acid to 0.1% trifluoroacetic acid. Pure fractions containing the correct TBMB-modified material were pooled, lyophilised
30 and kept at -20°C for storage.

All amino acids, unless noted otherwise, were used in the L- configurations.

In some cases peptides are converted to activated disulfides prior to coupling with the free
35 thiol group of a toxin using the following method; a solution of 4-methyl(succinimidyl 4-(2-pyridylthio)pentanoate) (100mM) in dry DMSO (1.25 mol equiv) was added to a solution of

peptide (20mM) in dry DMSO (1 mol equiv). The reaction was well mixed and DIPEA (20 mol equiv) was added. The reaction was monitored by LC/MS until complete.

BIOLOGICAL DATA

5 *Human Fluorescence Polarisation Competition Binding Assay*

Due to its high affinity to the MT1-MMP Hemopexin domain (PEX), the fluoresceinated derivative of 17-88-N006 (SEQ ID NO: 28) can be used for competition experiments (using FP for detection). Here, a preformed complex of PEX with the fluorescent PEX-binding tracer (in all experiments - ACPYSWETCLFGDYRCA[Sar]₆[KFI] (17-88-N006) (SEQ ID NO: 28)) is
10 titrated with free, non-fluoresceinated bicyclic peptide. Since all 17-69-based peptides are expected to bind at the same site, the titrant will displace the fluorescent tracer from PEX. Dissociation of the complex can be measured quantitatively, and the K_d of the competitor (titrant) to the target protein determined. The advantage of the competition method is that the affinities of non-fluoresceinated bicyclic peptides can be determined accurately and rapidly.
15 Concentrations of tracer are usually at the K_d or below (here, 1 nM), and the binding protein (here, hemopexin of MT1-MMP) is at a 15-fold excess such that >90% of the tracer is bound. Subsequently, the non-fluorescent competitor bicyclic peptide (usually just the bicycle core sequence) is titrated, such that it displaces the fluorescent tracer from the target protein. The displacement of the tracer is measured and associated with a drop in fluorescence
20 polarisation. The drop in fluorescence polarisation is proportional to the fraction of target protein bound with the non-fluorescent titrant, and thus is a measure of the affinity of titrant to target protein.

The raw data is fit to the analytical solution of the cubic equation that describes the equilibria
25 between fluorescent tracer, titrant, and binding protein. The fit requires the value of the affinity of fluorescent tracer to the target protein, which can be determined separately by direct binding FP experiments (see next section). The curve fitting was performed using Sigmaplot 12.0 and used as an adapted version of the equation described by Zhi-Xin Wang (FEBS Letters (1995) 360, 111-114).

30

Selected peptides of the invention were tested in the above mentioned Human Fluorescence Polarisation competition binding assay and the results are shown in Table 1:

35

Table 1: Human MT1-MMP Fluorescence Polarisation Competition Binding

Bicyclic Peptide	Molecular Scaffold	K_i	n
BCY1025	TBMB	98.52 ± 29.34	10
BCY1027	TBMB	92.67 ± 68.46	3
BCY1029	TBMB	503	1
BCY1030	TBMB	670	1
BCY1031	TBMB	1100	1
BCY1032	TBMB	318.5 ± 181.3	2
BCY1034	TBMB	406	1
BCY1035	TBMB	391	1
BCY1036	TBMB	103.3 ± 31.52	4
BCY1037	TBMB	908	1
BCY1038	TBMB	1500	1
BCY1039	TBMB	177	1
BCY1040	TBMB	88.8	1
BCY1041	TBMB	178	1
BCY1042	TBMB	89.45 ± 4.02	2
BCY1043	TBMB	275	1
BCY1044	TBMB	109	1
BCY1045	TBMB	155	1
BCY1046	TBMB	510	1
BCY1047	TBMB	223	1
BCY1048	TBMB	124	1
BCY1049	TBMB	63.45 ± 8.91	23
BCY1051	TBMB	124.6 ± 63.5	2
BCY1052	TBMB	490	1
BCY1053	TBMB	358	1
BCY1054	TBMB	848	1
BCY1056	TBMB	287	1
BCY1388	TBMB	81.35 ± 32.63	2

Human Fluorescence Polarisation Direct Binding Assay

- 5 Direct Binding Fluorescence Polarisation or Anisotropy Assays are performed by titrating a constant concentration of fluorescent tracer (here, the fluoresceinated bicyclic peptide to be studied) with its binding partner (here, the MT1-MMP hemopexin domain). As the

concentration of binding partner increases during the titration, the polarisation signal changes in proportion to the fraction of bound and unbound material. This allows determination of dissociation rates (K_d) quantitatively. Assay data can be fit using standard ligand binding equations.

5

Typically, concentrations of the tracer are ideally well below the K_d of the tracer:titrant pair, and concentrations chosen are usually at ~ 1 nM or less. The titrant (binding partner) concentration is varied from 0.1 nM up to typically 5 μ M. The range is chosen such that the maximum change in fluorescent polarisation can be observed. Buffers employed are phosphate buffered saline in the presence of 0.01 % Tween. Experiments were run in black 384 well low-bind/low volume plates (Corning 3820), and the fluorescent polarisation signal was measured using a BMG Pherastar FS plate reader. Fluorescent tracers referred to in the text are bicyclic peptides that have been fluoresceinated using 5,6-carboxyfluorescein. Fluoresceination may be performed on the N-terminal amino group of the peptide, which is separated from the bicycle core sequence by a sarcosine spacer (usually Sar5). This can be done during Fmoc solid phase synthesis or post-synthetically (after cyclisation with TBMB and purification) if the N-terminal amino group is unique to the peptide. Fluoresceination can also be performed on the C-terminus, usually on a Lysine introduced as the first C-terminal residue, which is then separated from the bicycle core sequence by a sarcosine spacer (usually Sar6). Thus, N-terminal tracers can have a molecular format described as Fluo-Gly-Sar6-A(BicycleCoreSequence), and (BicycleCoreSequence)-A-Sar6-K(Fluo) for a C-terminally fluoresceinated construct.

Fluorescent tracers used in the Examples include BCY1323-Sar6-K(FI), BCY1326-Sar6-K(FI), BCY3418-Sar6-K(FI), BCY3422-K(FI), and BCY1329-Sar6-K(FI). Due to the acidic nature of the fluorescent peptides, they were typically prepared as concentrated DMSO stocks, from which dilution were prepared in 100 mM Tris pH 8 buffer.

25

Selected peptides of the invention were tested in the above mentioned fluorescence polarisation direct binding assay and the results are shown in Table 2:

30

35

Table 2: Human MT1-MMP Fluorescence Polarisation Direct Binding

Bicyclic Peptide	Molecular Scaffold	K_d	n
BCY1323	TBMB	35.86 ± 6.65	20
BCY1325	TBMB	140	1
BCY1326	TBMB	218	1
BCY1327	TBMB	98.5	1
BCY1329	TBMB	22.05 ± 10.96	6

5

CLAIMS

1. A peptide ligand specific for the collagen binding site of MT1-MMP comprising a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and an aromatic molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold.
2. The peptide ligand as defined in claim 1, wherein said loop sequences comprise 6 amino acids.
3. The peptide ligand as defined in claim 1 or claim 2, wherein said loop sequences comprise three cysteine residues separated by two loop sequences both of which consists of 6 amino acids.
4. The peptide ligand as defined in any one of claims 1 to 3, wherein the peptide ligand comprises an amino acid sequence selected from:
 $C_i-X_1-X_2-X_3-X_4-X_5-X_6-C_{ii}-L-F-G-X_{10}-Y-X_{12}-C_{iii}$ (SEQ ID NO: 1)
 wherein X_1-X_6 , X_{10} and X_{12} represent any natural or non-natural amino acid and C_i , C_{ii} and C_{iii} represent first, second and third cysteine residues, respectively or a pharmaceutically acceptable salt thereof.
5. The peptide ligand as defined in claim 4, wherein:
 X_1 represents S, P, HyP or D; and/or
 X_2 represents F, L, Y, V, H or I; and/or
 X_3 represents D, S or E; and/or
 X_4 represents W, T, R or I; and/or
 X_5 represents W, E, D, S, R, A or H; and/or
 X_6 represents I, T, M, V, L or Q; and/or
 X_{10} represents D, E, N, S, T or Q; and/or
 X_{12} represents T, R, S, N, K, D or H.
6. The peptide ligand as defined in claim 4 or claim 5, wherein the peptide ligand of $C_i-X_1-X_2-X_3-X_4-X_5-X_6-C_{ii}-L-F-G-X_{10}-Y-X_{12}-C_{iii}$ (SEQ ID NO: 1) is selected from:
 CPYSWETCLFGDYRC (SEQ ID NO: 2);
 C[HyP]YSWETCLFGDYRC (SEQ ID NO: 3);
 CSLDWETCLFGDYRC (SEQ ID NO: 4);

CDVEWETCLFGDYRC (SEQ ID NO: 5);
 CPYSWDTCLFGDYRC (SEQ ID NO: 6);
 CPHDWETCLFGDYRC (SEQ ID NO: 7);
 CPYSWDMCLFGDYRC (SEQ ID NO: 8);
 5 CPYSWDVCLFGDYRC (SEQ ID NO: 9);
 CPYSWDLCLFGDYRC (SEQ ID NO: 10);
 CPYSWSQCLFGDYRC (SEQ ID NO: 11);
 CPYSWSTCLFGDYRC (SEQ ID NO: 12);
 CPYSWDICLFGDYRC (SEQ ID NO: 13);
 10 CPYSWRTCLFGDYRC (SEQ ID NO: 14);
 CPYSWETCLFGDYSC (SEQ ID NO: 15);
 CPYSWETCLFGEYNC (SEQ ID NO: 16);
 CPYSWETCLFGEYKC (SEQ ID NO: 17);
 CPYSWETCLFGNYTC (SEQ ID NO: 18);
 15 CPYSWETCLFGDYDC (SEQ ID NO: 19);
 CPYSWETCLFGSYRC (SEQ ID NO: 20);
 CPYSWETCLFGSYTC (SEQ ID NO: 21);
 CPYSWETCLFGTYTC (SEQ ID NO: 22);
 CPYDWATCLFGDYRC (SEQ ID NO: 23);
 20 CPYDTWTCLFGDYRC (SEQ ID NO: 24);
 CPYDRHTCLFGDYRC (SEQ ID NO: 25);
 CPYDIRTCLFGDYRC (SEQ ID NO: 26); and
 CPLSWSTCLFGQYHC (SEQ ID NO: 27);

such as:

25 A-(SEQ ID NO: 2)-A (BCY1025);
 Ac-(SEQ ID NO: 2) (BCY1027);
 [DOTA]-G-[Sar]₅-(SEQ ID NO: 2) (BCY1388);
 A-(SEQ ID NO: 3)-A (BCY1029);
 A-(SEQ ID NO: 4)-A (BCY1030);
 30 A-(SEQ ID NO: 5)-A (BCY1031);
 A-(SEQ ID NO: 6)-A (BCY1032);
 A-(SEQ ID NO: 7)-A (BCY1034);
 A-(SEQ ID NO: 8)-A (BCY1035);
 A-(SEQ ID NO: 9)-A (BCY1036);
 35 A-(SEQ ID NO: 10)-A (BCY1037);
 A-(SEQ ID NO: 11)-A (BCY1038);
 A-(SEQ ID NO: 12)-A (BCY1039);

A-(SEQ ID NO: 13)-A (BCY1040);
 A-(SEQ ID NO: 14)-A (BCY1041);
 A-(SEQ ID NO: 15)-A (BCY1042);
 A-(SEQ ID NO: 16)-A (BCY1043);
 5 A-(SEQ ID NO: 17)-A (BCY1044);
 A-(SEQ ID NO: 18)-A (BCY1045);
 A-(SEQ ID NO: 19)-A (BCY1046);
 A-(SEQ ID NO: 20)-A (BCY1047);
 A-(SEQ ID NO: 21)-A (BCY1048);
 10 A-(SEQ ID NO: 22)-A (BCY1049);
 A-(SEQ ID NO: 23)-A (BCY1051);
 A-(SEQ ID NO: 24)-A (BCY1052);
 A-(SEQ ID NO: 25)-A (BCY1053);
 A-(SEQ ID NO: 26)-A (BCY1054); and
 15 A-(SEQ ID NO: 27)-A (BCY1056).

7. The peptide ligand as defined in any one of claims 1 to 6, wherein the molecular scaffold is TBMB.

20 8. The peptide ligand as defined in claim 7, wherein the molecular scaffold is TBMB and the peptide ligand of C_i-X₁-X₂-X₃-X₄-X₅-X₆-C_{ii}-L-F-G-X₁₀-Y-X₁₂-C_{iii} (SEQ ID NO: 1) is selected from:

A-(SEQ ID NO: 2)-A (BCY1025);
 Ac-(SEQ ID NO: 2) (BCY1027);
 25 [DOTA]-G-[Sar]₅-(SEQ ID NO: 2) (BCY1388);
 A-(SEQ ID NO: 3)-A (BCY1029);
 A-(SEQ ID NO: 4)-A (BCY1030);
 A-(SEQ ID NO: 5)-A (BCY1031);
 A-(SEQ ID NO: 6)-A (BCY1032);
 30 A-(SEQ ID NO: 7)-A (BCY1034);
 A-(SEQ ID NO: 8)-A (BCY1035);
 A-(SEQ ID NO: 9)-A (BCY1036);
 A-(SEQ ID NO: 10)-A (BCY1037);
 A-(SEQ ID NO: 11)-A (BCY1038);
 35 A-(SEQ ID NO: 12)-A (BCY1039);
 A-(SEQ ID NO: 13)-A (BCY1040);
 A-(SEQ ID NO: 14)-A (BCY1041);

- 5 A-(SEQ ID NO: 15)-A (BCY1042);
A-(SEQ ID NO: 16)-A (BCY1043);
A-(SEQ ID NO: 17)-A (BCY1044);
A-(SEQ ID NO: 18)-A (BCY1045);
A-(SEQ ID NO: 19)-A (BCY1046);
A-(SEQ ID NO: 20)-A (BCY1047);
A-(SEQ ID NO: 21)-A (BCY1048);
A-(SEQ ID NO: 22)-A (BCY1049);
A-(SEQ ID NO: 23)-A (BCY1051);
10 A-(SEQ ID NO: 24)-A (BCY1052);
A-(SEQ ID NO: 25)-A (BCY1053);
A-(SEQ ID NO: 26)-A (BCY1054); and
A-(SEQ ID NO: 27)-A (BCY1056).
- 15 9. The peptide ligand as defined in any one of claims 1 to 8, wherein the pharmaceutically acceptable salt is selected from the free acid or the sodium, potassium, calcium, ammonium salt.
- 20 10. The peptide ligand as defined in any one of claims 1 to 9, wherein the MT1-MMP is human MT1-MMP.
11. A drug conjugate comprising a peptide ligand as defined in any one of claims 1 to 10, conjugated to one or more effector and/or functional groups.
- 25 12. The drug conjugate as defined in claim 11, conjugated to one or more cytotoxic agents.
13. The drug conjugate as defined in claim 12, wherein said cytotoxic agent is selected from MMAE or DM1.
- 30 14. A pharmaceutical composition which comprises the peptide ligand of any one of claims 1 to 10 or the drug conjugate of any one of claims 11 to 13, in combination with one or more pharmaceutically acceptable excipients.
- 35 15. The pharmaceutical composition as defined in claim 14, which additionally comprises one or more therapeutic agents.

16. The drug conjugate as defined in any one of claims 11 to 13, for use in preventing, suppressing or treating a disease or disorder mediated by MT1-MMP.

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2019/053539

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61P35/00 A61K38/00 C07K7/08 C12N9/64
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
A61P A61K C07K C12N
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2016/067035 A1 (BICYCLE THERAPEUTICS LTD [GB]) 6 May 2016 (2016-05-06) the whole document -----	1-16

Further documents are listed in the continuation of Box C.

See patent family annex.

- * Special categories of cited documents :
- "A" document defining the general state of the art which is not considered to be of particular relevance
 - "E" earlier application or patent but published on or after the international filing date
 - "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 - "O" document referring to an oral disclosure, use, exhibition or other means
 - "P" document published prior to the international filing date but later than the priority date claimed
 - "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 - "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 - "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 - "&" document member of the same patent family

Date of the actual completion of the international search 2 March 2020	Date of mailing of the international search report 11/03/2020
--	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer López García, F
--	--

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2019/053539

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2016067035	A1	06-05-2016	
		AU 2015340300 A1	11-05-2017
		BR 112017008575 A2	26-12-2017
		CA 2965754 A1	06-05-2016
		CN 107148425 A	08-09-2017
		EP 3215518 A1	13-09-2017
		JP 2018502825 A	01-02-2018
		KR 20170073611 A	28-06-2017
		RU 2017118326 A	29-11-2018
		RU 2019138346 A	13-12-2019
		SG 11201702845Q A	30-05-2017
		US 2018280525 A1	04-10-2018
		WO 2016067035 A1	06-05-2016
